Table 4.
Outcome measures
|
Sample groups
|
Baseline
|
One-month
|
P value
|
Effectiveness size
|
Power
|
GAD | VR (n = 23), mean (SD) | 2.88 (4.13) | 3.39 (3.60) | 0.341 | 0.128 | 0.9577 |
TAU (n = 17), mean (SD) | 4.32 (51.7) | 5.24 (5.56) | 0.64 | 0.0768 | 0.9951 | |
VR vs TAU1 | - | - | 0.702 | 0.0613 | 0.9974 | |
GSE | VR (n = 23), mean (SD) | 32.17 (4.13) | 31.78 (4.31) | 0.531 | 0.0833 | 0.9996 |
TAU (n = 17), mean (SD) | 31.14 (3.73) | 32.83 (4.75) | 0.147 | 0.237 | 0.7974 | |
VR vs TAU1 | - | - | 0.367 | 0.143 | 0.9717 |
Virtual reality vs treatment as usual comparison at one-month.
VR: Virtual reality; TAU: Treatment as usual; GAD: Generalised anxiety disorder assessment; GSE: General self-efficacy.